Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-982470 (recombinant interleukin-21), Denenicokin, rIL-21(recombinant interleukin 21)
BMS-982470 · 2 trials · 2 indications
Based on the dose-limiting toxicity (DLT) rate
Based on medical review of AE reports and the results of vital sign measurements, physical examinations, medical history, and clinical laboratory tests
| Arm | Type | Description |
|---|---|---|
| Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558 | EXPERIMENTAL | Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558 | EXPERIMENTAL | Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558 | EXPERIMENTAL | Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab | EXPERIMENTAL | Dose Escalation |
| Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab | EXPERIMENTAL | Dose Escalation |
| Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab | EXPERIMENTAL | Cohort Expansion |
| Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab | EXPERIMENTAL | Cohort Expansion |
| Part 2 - Arm 3: Ipilimumab monotherapy | ACTIVE_COMPARATOR | Cohort Expansion |
| Name | Type | Description |
|---|---|---|
| Denenicokin | BIOLOGICAL | - |
| Nivolumab | BIOLOGICAL | - |
| BMS-982470 (recombinant interleukin-21) | BIOLOGICAL | Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response |
| Ipilimumab | BIOLOGICAL | Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * All subjects will have locally advanced or metastatic solid tumors * For Part 2 (Cohort Expansion): * Tumor types will be restricted to clear cell renal cell carcinoma (cc...
Top 20 of 52 competitors
BMS-982470 is an investigational recombinant interleukin-21 therapy being developed by Bristol-Myers Squibb for the treatment of melanoma. It is a monoclonal antibody studied in a Phase 1 clinical trial in combination with ipilimumab. It is not approved and remains in clinical development.
BMS-982470 was studied for the treatment of melanoma, specifically in combination with ipilimumab in a Phase 1 safety trial. The study enrolled 42 participants with melanoma across the United States and Puerto Rico. BMS-982470 is investigational and has not been approved for any indication.
BMS-982470 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 melanoma trial evaluating BMS-982470 in combination with ipilimumab.
BMS-982470 is in Phase 1 clinical development. Its single trial, NCT01489059, has been completed, and no active trials are ongoing. BMS-982470 is investigational and has not received FDA approval for melanoma or any other indication.
BMS-982470 was evaluated in one clinical trial, NCT01489059, titled Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma. The Phase 1 trial enrolled 42 participants aged 18 and older in the United States and Puerto Rico and is now completed.
Yes, BMS-982470 is also known as recombinant interleukin-21. Both names refer to the same investigational Bristol-Myers Squibb agent studied in melanoma. Searches for either name point to the same Phase 1 program and the same completed trial, NCT01489059.